PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

It makes up about 70% of all breast cancer cases. HR+/HER2- breast cancer involves tumor cells that test positive for hormone receptors and negative for HER2 proteins. Cancer cells with estrogen or ...

Relacorilant was well tolerated. Notably, there were no instances of drug-induced adrenal insufficiency, hypokalemia or QT ...

Triple-positive breast cancer is a type of breast cancer that tests positive for estrogen receptors, progesterone receptors, and high levels of HER2 protein. Some types of breast cancer cells use ...